AR039249A1 - Derivados de fenilo 4 - Google Patents

Derivados de fenilo 4

Info

Publication number
AR039249A1
AR039249A1 ARP030101174A ARP030101174A AR039249A1 AR 039249 A1 AR039249 A1 AR 039249A1 AR P030101174 A ARP030101174 A AR P030101174A AR P030101174 A ARP030101174 A AR P030101174A AR 039249 A1 AR039249 A1 AR 039249A1
Authority
AR
Argentina
Prior art keywords
atoms
monosubstituted
hal
con
coor2
Prior art date
Application number
ARP030101174A
Other languages
English (en)
Inventor
Cezanne Bertram Dr
Mederski Werner Dr
Gleitz Johannes Dr
Dorsch Dieter Dr
Tsaklakidis Christos Dr
Barnes Christopher Dr
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR039249A1 publication Critical patent/AR039249A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Derivados de fenilo 4 de la fórmula (1) en donde D está ausente o es una cadena de alquileno saturada, completa o parcialmente no saturada de 3 a 4 miembros, en donde de 1 a 3 átomos de C pueden estar reemplazados por átomos de N y/o 1 o 2 átomos de C pueden estar reemplazados por 1 o 2 átomos de O y/o 1 o 2 átomos de S, pero donde a lo sumo están reemplazados hasta 3 átomos de C y donde, además, la cadena de alquileno y/o un N allí presente pueden estar monosustituidos, disustituidos o trisustituidos por Hal, A, -[C(R3)2]n-Ar, -[C(R3)2]n-Het, -[C(R3)2]n-cicloalquilo, OR2, N(R2)2, NO2, CN, COOR2, CON(R2)2, NR2COA, NR2SO2A, COR2, SO2NR2 y/o S(O)mA, y donde, además, un grupo de CH2 en la cadena de alquileno también puede estar reemplazado por un grupo C=O, M es un anillo fenilo o un anillo heterocíclico aromático que puede contener 1-2 átomos de N, O y/o S, R1 es H, Hal, A, OR2, N(R2)2, NO2, CN, COOR2, CON(R2)2, -[C(R3)2]n-Ar, -[C(R3)2]n-Het, -[C(R3)2]n-cicloalquilo, -[C(R3)2]n-N(R3)2, -CN, -C(=NH)-,NH2 que está insustituido o monosustituido por C(=O)R3, COOR3, OR3 o por un grupo de protección amino convencional, o restos de fórmulas (2) y (3); R2 es H, A, -[C(R3)2]n-Ar, -[C(R3)2]n-Het, -[C(R3)2]n-cicloalquilo, -[C(R3)2]n-N(R3)2 o -[C(R3)2]n-OR3, R2' es H, A, -[C(R3)2]n-Ar', -[C(R3)2]n-Het', -[C(R3)2]n-cicloalquilo, -[C(R3)2]n-N(R3)2 o -[C(R3)2]n-OR3, R2" es H, A, -[C(R3)2]n-Ar', -[C(R3)2]n-cicloalquilo, -[C(R3)2]n-N(R3)2 o -[C(R3)2]n-OR3; R3 es H o A; W es -C(R2)2, -[C(R2)2]2-, -OC(R3)2-, -NR2C(R2)2-, -NR2CO- o -CONR2-; X es CONR2, CONR2C(R3)2, -C(R3)2NR2, -C(R3)2NR2C(R3)2, -C(R3)2O- o C(R3)2OC(R3)2-, Y es alquileno, cicloalquileno, Het-diilo o Ar-diilo, T es un anillo carbocíclico o heterocíclico monocíclico o bicíclico, saturado, no saturado o aromático que tiene de 1 a 4 átomos de N, O y/o S que está monosustituido o disustituido por =S, =NR2, =NOR2, =NCOR2, =NCOOR2 o =NOCOR2 y también puede estar monosustituido, disustituido o trisustituido por Hal, A, -[C(R3)2]n-Ar, -[C(R3)2]n-Het, -[C(R3)2]n-cicloalquilo, OR3, N(R3)2, NO2, CN, COOR2, CON(R2)2, NR2COA, NR2CON(R2)2, NR2SO2A, COR2, SO2NR2 y/o S(O)mA, A es alquilo no ramificado o ramificado que tiene 1-10 átomos de carbono, en donde 1 o 2 grupos CH2 pueden estar reemplazados por átomos de O ó S y/o por grupos -CH=CH-, y/o además 1-7 átomos de H pueden estar reemplazados por F, Ar es fenilo, naftilo o bifenilo, cada uno de los cuales está insustituido o monosustituido, disustituido o trisustituido por Hal, A, OR3, N(R3)2, NO2, CN, COOR3, CON(R3)2, NR3COA, NR3CON(R3)2, NR3SO2A, COR3, SO2N(R3)2, S(O)mA, -[C(R3)2]n-COOR2' u -O-[C(R3)2]o-COOR2', Ar' es fenilo o bencilo, cada uno de los cuales está insustituido o monosustituido o disustituido por Hal o A, Het es un anillo heterocíclico monocíclico o bicíclico, saturado, no saturado o aromático que tiene de 1 a 4 átomos de N, O y/o S, que puede estar insustituido o monosustituido, disustituido o trisustituido por el O del carbonilo, =S, =N(R3)2, Hal, A, [C(R3)2]n-Ar, -[C(R3)2]n-Het1, -[C(R3)2]n-cicloalquilo, -[C(R3)2]n-OR2, -[C(R3)2]n-N(R2´)2, NO2, CN, -[C(R3)2]n-COOR2', -[C(R3)2]n-CON(R2')2, -[C(R3)2]n-NR2' COA, NR2' CON(R2')2, -[C(R3)2]n-NR2' SO2A, COR2', SO2NR2' y/o S(O)mA, Het1 es un anillo heterocíclico monocíclico o bicíclico, saturado, no saturado o aromático con 1 o 2 átomos de N, O y/o S, que puede estar insustituido o monosustituido o disustituido por el O del carbonilo, =S, =N(R3)2, Hal, A, OR2", N(R2")2, NO2, CN, COOR2", CON(R2")2, NR2"COA, NR2"CON(R2")2, NR2"SO2A, COR2", SO2NR2" y/o S(O)mA, Hal es F, Cl, Br, o I, n es 0, 1 o 2; m es 0, 1, o 2, o es 1, 2 o 3. Estos compuestos son inhibidores del factor de coagulación Xa y pueden emplearse para la profilaxis y/o la terapia de enfermedades tromboenbólicas y para el tratamiento de tumores.
ARP030101174A 2002-04-04 2003-04-04 Derivados de fenilo 4 AR039249A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10214832A DE10214832A1 (de) 2002-04-04 2002-04-04 Phenylderivate 4

Publications (1)

Publication Number Publication Date
AR039249A1 true AR039249A1 (es) 2005-02-16

Family

ID=28051091

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101174A AR039249A1 (es) 2002-04-04 2003-04-04 Derivados de fenilo 4

Country Status (10)

Country Link
US (1) US20050176760A1 (es)
EP (1) EP1490056B1 (es)
JP (1) JP2005528377A (es)
AR (1) AR039249A1 (es)
AT (1) ATE337779T1 (es)
AU (1) AU2003214102A1 (es)
CA (1) CA2481026A1 (es)
DE (2) DE10214832A1 (es)
ES (1) ES2271539T3 (es)
WO (1) WO2003084533A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517589A (ja) 2003-02-11 2006-07-27 ブリストル−マイヤーズ　スクイブ　カンパニー セリンプロテアーゼ・インヒビターとして有用なベンゼンアセトアミド化合物
EP1594505A4 (en) 2003-02-11 2008-08-13 Bristol Myers Squibb Co PHENYLGLYCIN DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS
EP1479680A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Azaindole derivatives as Factor Xa inhibitors
TW200637843A (en) 2005-01-10 2006-11-01 Bristol Myers Squibb Co Phenylglycinamide derivatives useful as anticoagulants
ES2382876T3 (es) 2005-05-31 2012-06-14 Pfizer, Inc. Compuestos de ariloxi-N-biciclometil-acetamida sustituidos como antagonistas de VR1
WO2007002313A2 (en) * 2005-06-24 2007-01-04 Bristol-Myers Squibb Company Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
US7625890B2 (en) 2005-11-10 2009-12-01 Smithkline Beecham Corp. Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
AU2007215247B2 (en) * 2006-02-10 2012-12-13 Transtech Pharma, Llc Benzazole derivatives, compositions, and methods of use as Aurora kinase inhibitors
US8440662B2 (en) 2010-10-31 2013-05-14 Endo Pharmaceuticals, Inc. Substituted quinazoline and pyrido-pyrimidine derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2540109B1 (fr) * 1983-01-28 1985-08-30 Logeais Labor Jacques Imino-2 pyrrolidines, leur procede de preparation et leurs applications en therapeutique
EP1196379A2 (en) * 1999-05-24 2002-04-17 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
CA2382751A1 (en) * 1999-05-24 2000-11-30 Cor Therapeutics, Inc. Inhibitors of factor xa
DE10027025A1 (de) * 2000-05-31 2001-12-06 Merck Patent Gmbh Clycinamide
DE10102322A1 (de) * 2001-01-19 2002-07-25 Merck Patent Gmbh Phenylderivate

Also Published As

Publication number Publication date
JP2005528377A (ja) 2005-09-22
CA2481026A1 (en) 2003-10-16
DE50304858D1 (de) 2006-10-12
ATE337779T1 (de) 2006-09-15
WO2003084533A1 (de) 2003-10-16
AU2003214102A1 (en) 2003-10-20
ES2271539T3 (es) 2007-04-16
US20050176760A1 (en) 2005-08-11
EP1490056B1 (de) 2006-08-30
EP1490056A1 (de) 2004-12-29
DE10214832A1 (de) 2003-10-16

Similar Documents

Publication Publication Date Title
AR040472A1 (es) Derivado de 2-(fenil)-2h-pirazol-3-carboxilico-n-4(tioxo-heterociclil)fenil-amida e imino-heterociclil derivados y compuestos relacionados, procedimiento, medicamentos, kit
EA200300354A1 (ru) Хинолиноновые производные в качестве ингибиторов тирозинкиназы
CO4600675A1 (es) Derivados de oxalilamino-benzofurano y benzotienilo
HUP0105414A2 (hu) Pirrolo-izokinolin-, azepino- és diazepino-indol-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
AR039249A1 (es) Derivados de fenilo 4
ES2140654T3 (es) 1,2,3,4-tetrahidro-5-nitro-pirimidinas substituidas.
ES2191484T3 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa.
AR036032A1 (es) Compuesto derivado de quinolina, composicion que lo comprende; uso del mismo en la fabricacion de medicamentos, proceso para prepararlo, y metodo para detectar y seleccionar un agente que module la actividad del mif
BR9813480A (pt) Compostos inibidores de neuraminidase de ciclopentano substituìdo, composição e métodos de inibição da neuraminidase do vìrus da influenza- e de tratamento de infecção por vìrus da influenza-
EA200500893A1 (ru) Трициклические соединения, представляющие собой ингибиторы протеинкиназ, для увеличения эффективности противоопухолевых агентов и лучевой терапии
BRPI0412761A (pt) inibidores de serino proteases, particularmente a protease ns3-ns4a do vhc
EA200400944A1 (ru) Замещенные производные тетрациклина, фармацевтическая композиция и способ лечения субъекта с их использованием
ATE369845T1 (de) Behandlung der nebenwirkungen von statinen
RU2002120515A (ru) Гетероциклические соединения, содержащие сульфонамидные группы
AR054799A1 (es) Derivados de oxindol
EE03139B1 (et) Piperasiiniderivaadid, nende kasutamine ja farmatseutiline kompositsioon
NZ512864A (en) Triazole compounds with dopamine-D3-receptor affinity
AR050045A1 (es) Derivados de pirrolo[3,4-c]pirazol activos como inhibidores de quinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden
YU18999A (sh) Supstituisani tricikli
DE69332357D1 (de) Verwendung von methioninase als antitumormittel in der antimethionin-chemotherapie
PE20040472A1 (es) Composiciones inhibidoras de la arn polimerasa dependiente de arn del virus de la hepatitis c
AR035317A1 (es) Derivados de purina, su procedimiento de preparacion, medicamentos, composiciones farmaceuticas y utilizacion de compuestos para la preparacion de medicamentos
PE79599A1 (es) Derivados de 5'-desoxicitidina
HUP0400362A2 (hu) Antiaritmiás hatású helyettesített benzopiránszármazékok
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero

Legal Events

Date Code Title Description
FB Suspension of granting procedure